Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

1 Study Matches

Safety, efficacy and exposure of subcutaneously administered NNC0365-3769 (Mim8) prophylaxis in children with hemophilia A with or without FVIII inhibitors

This is a drug study that will examine the safety and effectiveness of once-weekly and once-monthly Mim8 treatment in children (age 1-11 years) with hemophilia A with or without factor VIII (FVIII) inhibitors.

The study will last for about 54-98 weeks depending on how long a child will be followed before they start receiving Mim8. Once the treatment starts, the child will receive the medicine once a week for the first 26 weeks. There will be 12-17 clinical visits. Blood will be drawn at 13 of the visits.

$75 per visit to cover travel expenses

M. Elaine Eyster
Bree Kelly - at or 717-531-0003, ext=281498

Younger than 18 years old
This study is NOT accepting healthy volunteers
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Congenital haemophilia A of any severity based on medical records
Pt in need of treatment with factor VIII or bypassing agent in the 26 weeks prior to screening
Age 1-11 years
Patients with endogenous FVIII activity >/= 1% must have at least 1 treated bleed within 6 months of screening
For patients previously untreated with FVIII must have severe haemophilia A (FVIII activity < 1%)

Exclusion Criteria:
Previous or current treatment for thromboembolic disease or signs of thromboembolic disease
Immune tolerance induction planned after treatment initiation
Exposure to non-factor haemostatic productsfor bleeding prophylaxix within 6 months prior to first dose
Pts with body weight below 3 kg at screening
Blood Disorders
I'm interested
Share via email
See this study on
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,